M Stetler-Stevenson

Summary

Affiliation: National Institutes of Health
Country: USA

Publications

  1. ncbi request reprint Tissue inhibitor of matrix metalloproteinase-1 overexpression in M1 myeloblasts impairs IL-6-induced differentiation
    Peter Haviernik
    Hematopoiesis Department, American Red Cross, Jerome H Holland Laboratory for the Biomedical Sciences, Rockville, MD 20855, USA
    Oncogene 23:9212-9. 2004
  2. ncbi request reprint Flow cytometric immunophenotypic profiles of mature gamma delta T-cell malignancies involving peripheral blood and bone marrow
    Ejaz Ahmad
    Department of Pathology, Good Samaritan Hospital, Dayton, Ohio, USA
    Cytometry B Clin Cytom 67:6-12. 2005
  3. doi request reprint Quantification of expression of antigens targeted by antibody-based therapy in chronic lymphocytic leukemia
    Prashant R Tembhare
    Flow Cytometry Unit, Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 10 Center Dr, Bethesda, MD, 20892
    Am J Clin Pathol 140:813-8. 2013
  4. doi request reprint Diagnosis of hairy cell leukemia by flow cytometry
    Maryalice Stetler-Stevenson
    Flow Cytometry Unit, Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Leuk Lymphoma 52:11-3. 2011
  5. doi request reprint Myelodysplastic syndromes: the role of flow cytometry in diagnosis and prognosis
    M Stetler-Stevenson
    Flow Cytometry Unit, Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Building 10, Room 2A 33, Mail Stop 1500, Bethesda, MD 20895, USA
    Int J Lab Hematol 31:479-83. 2009
  6. ncbi request reprint 2006 Bethesda International Consensus Conference on Flow Cytometric Immunophenotyping of Hematolymphoid Neoplasia
    Maryalice Stetler-Stevenson
    Laboratory of Pathology, NCI, NIH, Bethesda, Maryland 20892, USA
    Cytometry B Clin Cytom 72:S3. 2007
  7. ncbi request reprint Flow cytometry in lymphoma diagnosis and prognosis: useful?
    Maryalice Stetler-Stevenson
    Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Building 10, Room 2N 108, Mail Stop 1500, Bethesda, MD 20892, USA
    Best Pract Res Clin Haematol 16:583-97. 2003
  8. ncbi request reprint Diagnostic utility of flow cytometric immunophenotyping in myelodysplastic syndrome
    M Stetler-Stevenson
    Laboratory of Pathology and the Biostatistics, Division of Clinical Sciences, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Blood 98:979-87. 2001
  9. ncbi request reprint Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia
    R J Kreitman
    Laboratory of Molecular Biology, National Cancer Institute, Bethesda, MD 20892, USA
    N Engl J Med 345:241-7. 2001
  10. pmc A novel lymphoproliferative/autoimmune syndrome resembling murine lpr/gld disease
    M C Sneller
    Laboratory of Clinical Investigation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892
    J Clin Invest 90:334-41. 1992

Collaborators

Detail Information

Publications38

  1. ncbi request reprint Tissue inhibitor of matrix metalloproteinase-1 overexpression in M1 myeloblasts impairs IL-6-induced differentiation
    Peter Haviernik
    Hematopoiesis Department, American Red Cross, Jerome H Holland Laboratory for the Biomedical Sciences, Rockville, MD 20855, USA
    Oncogene 23:9212-9. 2004
    ..Intrinsic TIMP-1 expression in myeloid leukemia cells might thus impact upon survival or differentiation...
  2. ncbi request reprint Flow cytometric immunophenotypic profiles of mature gamma delta T-cell malignancies involving peripheral blood and bone marrow
    Ejaz Ahmad
    Department of Pathology, Good Samaritan Hospital, Dayton, Ohio, USA
    Cytometry B Clin Cytom 67:6-12. 2005
    ..In this study we compared clinical findings with flow cytometric immunophenotypic results in a series of patients with aggressive and indolent gamma delta T-cell malignancies with peripheral blood and/or bone marrow involvement...
  3. doi request reprint Quantification of expression of antigens targeted by antibody-based therapy in chronic lymphocytic leukemia
    Prashant R Tembhare
    Flow Cytometry Unit, Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 10 Center Dr, Bethesda, MD, 20892
    Am J Clin Pathol 140:813-8. 2013
    ..Studies suggest that levels of surface antigen expression may affect response to monoclonal antibody-based therapy...
  4. doi request reprint Diagnosis of hairy cell leukemia by flow cytometry
    Maryalice Stetler-Stevenson
    Flow Cytometry Unit, Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Leuk Lymphoma 52:11-3. 2011
    ..FCI is extremely sensitive in the detection of minimal disease and is useful in monitoring response to therapy...
  5. doi request reprint Myelodysplastic syndromes: the role of flow cytometry in diagnosis and prognosis
    M Stetler-Stevenson
    Flow Cytometry Unit, Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Building 10, Room 2A 33, Mail Stop 1500, Bethesda, MD 20895, USA
    Int J Lab Hematol 31:479-83. 2009
    ..In addition, flow cytometric analysis provides prognostic information in MDS that is not available from other sources. The flow cytometric findings indicative of MDS and its value is a diagnostic adjunct are discussed...
  6. ncbi request reprint 2006 Bethesda International Consensus Conference on Flow Cytometric Immunophenotyping of Hematolymphoid Neoplasia
    Maryalice Stetler-Stevenson
    Laboratory of Pathology, NCI, NIH, Bethesda, Maryland 20892, USA
    Cytometry B Clin Cytom 72:S3. 2007
  7. ncbi request reprint Flow cytometry in lymphoma diagnosis and prognosis: useful?
    Maryalice Stetler-Stevenson
    Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Building 10, Room 2N 108, Mail Stop 1500, Bethesda, MD 20892, USA
    Best Pract Res Clin Haematol 16:583-97. 2003
    ..The unique attributes of flow cytometry therefore make it a valuable technique in the diagnosis and classification of lymphomas as well as the assessment of prognostic markers in lymphoma patients...
  8. ncbi request reprint Diagnostic utility of flow cytometric immunophenotyping in myelodysplastic syndrome
    M Stetler-Stevenson
    Laboratory of Pathology and the Biostatistics, Division of Clinical Sciences, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Blood 98:979-87. 2001
    ..It is concluded that flow cytometric immunophenotyping may help establish the diagnosis of MDS, especially when morphology and cytogenetics are indeterminate. (Blood. 2001;98:979-987)..
  9. ncbi request reprint Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia
    R J Kreitman
    Laboratory of Molecular Biology, National Cancer Institute, Bethesda, MD 20892, USA
    N Engl J Med 345:241-7. 2001
    ..We tested the safety and efficacy of an immunotoxin directed against a surface antigen that is strongly expressed by leukemic hairy cells...
  10. pmc A novel lymphoproliferative/autoimmune syndrome resembling murine lpr/gld disease
    M C Sneller
    Laboratory of Clinical Investigation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892
    J Clin Invest 90:334-41. 1992
    ..The clinical and immunological features of this syndrome resemble the lymphoproliferative/autoimmune disease seen in lpr and gld mice...
  11. ncbi request reprint A phase I study of combination therapy with immunotoxins IgG-HD37-deglycosylated ricin A chain (dgA) and IgG-RFB4-dgA (Combotox) in patients with refractory CD19(+), CD22(+) B cell lymphoma
    R A Messmann
    Developmental Therapeutics Program, Clinical Trials Unit, Medicine Branch, National Cancer Institute, Bethesda, Maryland 20892 1906, USA
    Clin Cancer Res 6:1302-13. 2000
    ....
  12. ncbi request reprint Elevation of soluble CD307 (IRTA2/FcRH5) protein in the blood and expression on malignant cells of patients with multiple myeloma, chronic lymphocytic leukemia, and mantle cell lymphoma
    T Ise
    Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
    Leukemia 21:169-74. 2007
    ..Because CD307 is present on malignant cells from patients with MM, CLL and MCL, CD307 may be a useful therapeutic target for the treatment of these diseases...
  13. ncbi request reprint Flow cytometric analysis of lymphomas and lymphoproliferative disorders
    M Stetler-Stevenson
    Flow Cytometry Unit, Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Semin Hematol 38:111-23. 2001
    ..Semin Hematol 38:111-123. This is a US government work. There no restrictions on its use...
  14. ncbi request reprint Coincident myelodysplastic syndrome and T-cell large granular lymphocytic disease: clinical and pathophysiological features
    Y Saunthararajah
    Hematology Branch, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD, USA
    Br J Haematol 112:195-200. 2001
    ..The lower response rate of MDS or T-LGL/MDS to immunosuppression, compared with T-LGL alone, may reflect the older age and intrinsic stem cell abnormalities in MDS and T-LGL/MDS patients...
  15. ncbi request reprint Malignant thymoma associated with T-cell lymphocytosis. A case report with immunophenotypic and gene rearrangement analysis
    L J Medeiros
    Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892
    Arch Pathol Lab Med 117:279-83. 1993
    ..Thus, we suggest that the lymphocytosis results from a poorly defined immunoregulatory disorder, related to the presence of thymoma, and perhaps secondary thymic hormone imbalance...
  16. ncbi request reprint Tissue inhibitor of metalloproteinases 1 regulation of interleukin-10 in B-cell differentiation and lymphomagenesis
    L Guedez
    Flow Cytometry Unit and the Extracellular Matrix Pathology Section, Laboratory of Pathology, and the Biostatistics and Data Management Section, Division of Clinical Sciences, National Cancer Institute, Bethesda, MD 20892, USA
    Blood 97:1796-802. 2001
    ..Thus, TIMP-1 regulates IL-10 expression in B-cell NHL and, through the inhibition of apoptosis, appears responsible for the negative prognosis associated with IL-10 expression in these tumors...
  17. pmc IL-7 administration to humans leads to expansion of CD8+ and CD4+ cells but a relative decrease of CD4+ T-regulatory cells
    Steven A Rosenberg
    Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892 1201, USA
    J Immunother 29:313-9. 2006
    ..These studies suggest an important role for interleukin-7 in the treatment of patients with lymphopenia...
  18. pmc TIMP1 induces CD44 expression and the activation and nuclear translocation of SHP1 during the late centrocyte/post-germinal center B cell differentiation
    Young Sik Kim
    Department of Pathology, Korea University Ansan Hospital, 516 Gojan 1 dong, Danwon gu, Gyeonggi Do, Ansan 425 707, Republic of Korea
    Cancer Lett 269:37-45. 2008
    ..These results suggest that TIMP1 functions as a differentiating and survival factor of GC B cells by modulating CD44 and SHP1 in the late centrocyte/post-GC stage, regardless of EBV infection...
  19. ncbi request reprint Characterization of T-cell repertoire in hairy cell leukemia patients before and after recombinant immunotoxin BL22 therapy
    Evgeny Arons
    Laboratories of Molecular Biology and Pathology, and Biostatistics and Data Management Section, Centers for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
    Cancer Immunol Immunother 55:1100-10. 2006
    ....
  20. pmc FCRL1 on chronic lymphocytic leukemia, hairy cell leukemia, and B-cell non-Hodgkin lymphoma as a target of immunotoxins
    Xing Du
    Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892 4264, USA
    Blood 111:338-43. 2008
    ..Our results suggest that anti-FCRL1 immunotoxin E9(Fv)-PE38 exhibits remarkably specific cytotoxicity and merits further evaluation for the treatment of FCRL1-positive malignancies, including CLL, HCL, FL, MCL, and other B-NHL...
  21. ncbi request reprint Phase I trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with B-cell malignancies
    Robert J Kreitman
    Laboratory of Molecular Biology, National Cancer Institute, National Institutes of Health, Bldg 5124b, 9000 Rockville Pike, Bethesda, MD 20892, USA
    J Clin Oncol 23:6719-29. 2005
    ..To conduct a phase I trial of recombinant immunotoxin BL22, an anti-CD22 Fv fragment fused to truncated Pseudomonas exotoxin...
  22. ncbi request reprint CD2 is expressed by a subpopulation of normal B cells and is frequently present in mature B-cell neoplasms
    Douglas W Kingma
    Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    Cytometry 50:243-8. 2002
    ..Although CD2+ B-cells have been identified in normal fetal and postnatal thymus, they have not been reported in adults...
  23. ncbi request reprint Minimal residual disease detection in hairy cell leukemia. Comparison of flow cytometric immunophenotyping with clonal analysis using consensus primer polymerase chain reaction for the heavy chain gene
    Justin E Sausville
    Laboratory of Pathology, Bldg 10, Room 2N 108, Mail Stop 1500, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Am J Clin Pathol 119:213-7. 2003
    ..FC was adequate in 86 cases (100%), while cpPCR was adequate in 74 cases (86%). FC is superior to cpPCR for detecting minimal residual HCL. It is more sensitive and more specific and permits quantitation of tumor cell number...
  24. ncbi request reprint ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile
    Adrian Wiestner
    Metabolism Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892
    Blood 101:4944-51. 2003
    ..We developed reverse transcriptase-polymerase chain reaction and immunohistochemical assays for ZAP-70 expression that can be applied clinically and would yield important prognostic information for patients with CLL...
  25. ncbi request reprint Clinical quantitative flow cytometry: "Identifying the optimal methods for clinical quantitative flow cytometry"
    Gerald E Marti
    Division of Cell Gene Therapy, Food and Drug Administration, Bethesda, Maryland 20892, USA
    Cytometry B Clin Cytom 55:59. 2003
  26. ncbi request reprint Tissue inhibitor of metalloproteinase 1 (TIMP-1) promotes plasmablastic differentiation of a Burkitt lymphoma cell line: implications in the pathogenesis of plasmacytic/plasmablastic tumors
    Liliana Guedez
    Cell and Cancer Biology Branch and Hematopathology Section, Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA
    Blood 105:1660-8. 2005
    ..These findings strongly support TIMP-1 as an important factor in the pathogenesis of plasmacytic/plasmablastic tumors...
  27. ncbi request reprint T-cell lymphoblastic leukemia/lymphoma syndrome with eosinophilia and acute myeloid leukemia
    Lawrence S Lamb
    Department of Pediatrics, Division of Hematology and Oncology, University of South Carolina School of Medicine, Columbia, South Carolina, USA
    Cytometry B Clin Cytom 65:37-41. 2005
    ..This case also illustrates the importance of an interactive multidisciplinary approach to the laboratory evaluation of a leukemia patient...
  28. pmc Soluble CD22 as a tumor marker for hairy cell leukemia
    Kakushi Matsushita
    Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20854 4255, USA
    Blood 112:2272-7. 2008
    ..Trials are listed on www.cancer.gov as NCT00002765, NCT00021983, NCT00074048, NCT00085085, NCT00337311, and NCT00462189...
  29. ncbi request reprint Immunophenotypic features distinguishing familial chronic lymphocytic leukemia from sporadic chronic lymphocytic leukemia
    Ejaz Ahmad
    Good Samaritan Hospital, Dayton, Ohio, USA
    Cytometry B Clin Cytom 74:221-6. 2008
    ..To date no study has been conducted to evaluate and compare patterns of cell surface antigen expression in familial CLL and sporadic CLL...
  30. pmc PRAME expression in hairy cell leukemia
    Evgeny Arons
    Laboratories of Molecular Biology and Clinical Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892 4255, United States
    Leuk Res 32:1400-6. 2008
    ..We conclude that HCL and CLL differ in PRAME overexpression, and that basal normal expression of PRAME may limit its usefulness for following patients with minimal residual CLL or HCL...
  31. ncbi request reprint Bioethical considerations of monoclonal B-cell lymphocytosis: donor transfer after haematopoietic stem cell transplantation
    Nancy M Hardy
    Experimental Transplantation and Immunology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
    Br J Haematol 139:824-31. 2007
    ..Identification of MBL among prospective sibling transplant donors will become a common occurrence in transplant practice as transplantation is increasingly offered to older individuals and those with CLL...
  32. ncbi request reprint B-cell repertoire and clonal analysis in unaffected first degree relatives in familial chronic lymphocytic leukaemia kindred
    Fatima Abbasi
    Center for Biologics Evaluation and Research, US Food and Drug Administration, NIH, Bethesda, MD, USA
    Br J Haematol 139:820-3. 2007
    ..Three of these individuals all showed evidence of hyper-somatic mutations. The B-cell repertoire in unaffected FDR in familial CLL offers a new area to investigate the interface between the immune system and lymphoid neoplasm...
  33. ncbi request reprint Immunoglobulin light chain repertoire in hairy cell leukemia
    Evgeny Arons
    Laboratories of Molecular Biology and Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892 4255, USA
    Leuk Res 31:1231-6. 2007
    ..In HCL, we confirm the lack of kappa predominance observed in normal lymphocytes and in chronic lymphocytic leukemia, and note over-representation of several light chain genes...
  34. ncbi request reprint Minimal residual disease in hairy cell leukemia patients assessed by clone-specific polymerase chain reaction
    Evgeny Arons
    Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892 4255, USA
    Clin Cancer Res 12:2804-11. 2006
    ..Thus, patient-specific RQ-PCR is the most sensitive test for MRD in HCL patients and could be used to determine maximal response in patients obtaining multiple cycles of nonmyelotoxic biological treatment for this disease...
  35. ncbi request reprint Detection of malignant hematopoietic cells in cerebral spinal fluid previously diagnosed as atypical or suspicious
    Malcolm Schinstine
    Cytopathology Section, Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892 1500, USA
    Cancer 108:157-62. 2006
    ..In cases with low numbers of cells or ambiguous morphology, the diagnoses of "atypical" or "suspicious" may be used. The significance of these diagnostic terms in this scenario has not been well established...
  36. ncbi request reprint Vaccine-induced tumor-specific immunity despite severe B-cell depletion in mantle cell lymphoma
    Sattva S Neelapu
    Experimental and Transplantation Immunology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 10 Center Drive, Bethesda, Maryland 20892, USA
    Nat Med 11:986-91. 2005
    ..Based on these results, it is justifiable to administer vaccines in the setting of B-cell depletion; however, vaccine boosts after B-cell recovery may be necessary for optimal humoral responses...
  37. ncbi request reprint High incidence of occult leptomeningeal disease detected by flow cytometry in newly diagnosed aggressive B-cell lymphomas at risk for central nervous system involvement: the role of flow cytometry versus cytology
    Upendra Hegde
    Experimental Transplantation and Immunology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health Bethesda, MD 20892 1868, USA
    Blood 105:496-502. 2005
    ..Patients at risk for CNS spread should undergo staging CSF evaluation by flow cytometry...
  38. ncbi request reprint Adult T-cell leukemia/lymphoma: a cytopathologic, immunocytochemical, and flow cytometric study
    Laila Dahmoush
    National Institutes of Health National Cancer Institute, Section of Cytopathology, Bethesda, Maryland 20892, USA
    Cancer 96:110-6. 2002
    ..Adult T-cell leukemia/lymphoma (ATLL) is a postthymic lymphoproliferative neoplasm of T cells caused by human T-cell lymphotropic virus (HTLV-1). Most cases are found in Japan, the Caribbean basin, and West Africa...